Blue Horseshoe Stocks: Cannabis Stock Resurgence

Marijuana Stocks Making a Comeback

The biggest standout of yesterday’s session was the unmistakable resurgence of the cannabis sector. Many of you will recall that we have tracked this sector throughout the year, and indeed, dating much further back than that. The gains we’ve seen from this market in 2014 have been nothing short of historical. Over the past few months, however, we had been witnessing a huge beatback sector-wide, with pot plays steadily declining across the board.

You can see below from the random chart examples we’ve pulled, that similar action has been occuring in most every related stock. Familiar plays like HEMP, TRTC, and GRNH all exhibit strikingly similar paths. Steady, heavy losses followed by distinct signs of a turnaround.

Presumably the pickup we’re seeing as we head into the end into week’s end is due at least in part to campaign season kicking off for proponents of cannabis in places like Alaska, Florida, Oregon and Washington, D.C, who will all be voting on marijuana initiatives in some form or other on November 4th.

Other states are sure to be paying attention, especially those that are tight on cash. Colorado estimates that tax revenues from its first year of recreational sales stand at $60-70M. Meanwhile, Washington State’s measure roll-out of retail sales continues slowly, with only the second Seattle marijuana outlet scheduled to open up next Tuesday.  In a study conducted by NerdWallet.com, the nationwide legalization of pot would produce over $3B annually.

So here we are, having waited patiently for the marijuana space to begin to heat up again, finally seeing the kind of rebound activity that can provide us with quick in-and-out gains. We’re going to want to watch anything even remotely tied to the industry as voting time draws even closer.


Extended Watchlist:
RPRX, CNET, NAVB, DRYS, GALE

Blue Horseshoe Stocks: LPCN Recap, LPDX & More

Lipocine, Inc. LPCN

LPCN served up an opportunity at some decent intraday gains after appearing on yesterday morning’s extended watchlist.

The stock played out a classic dip and rip scenario, falling to a morning low of 6.89 before surging back in the afternoon to a subsequent high of 8.42. That offered traders a chance at intraday gains of up to 22% on plenty of liquidity- the stock would trade 23.5X its 30-day average volume.

The productive session came on the heels of the company announcing favorable results from Phase-3 clinical testing of “LPCN 1021”, its oral treatment for low testosterone >>> VIEW PR


LipoScience, Inc. LPDX

LPDX is gapping up heavily in the premarket, and the interesting story behind it is one that we’re definitely going to want to give our close attention. Early this morning, the company announced that it was the subject of a buyout that would be executed at a share price of $5.25. Barely an hour later, another PR hit the LPDX newswire, concerning an investigation of the managerial board’s handling of the deal, and whether or not they have secured the best possible buyout price.

According to the investigative firm leading the case, “The $5.25 per share acquisition price is far less than where the stock has recently traded. In fact, on January 25, 2013, LipoScience stock opened for trading at $9.75 the day the Company sold 5.0 million shares of stock in its initial public stock offering.” >>> VIEW PR

The playing out of this scenario is going to be an interesting story moving forward, which is why we wanted to flag LPDX this morning, and fill everyone in on this morning’s happenings. The possibility that the investigation could lead to a potential restructuring of the buyout is enough to have us keep our ears to the tracks on this one for the foreseeable future.


Magnum Hunter Resources Corp. MHR

MHR is another morning gapper that we’re putting on our radars. This morning Magnum announced impressive throughput volumes on its “Eureka Hunter” gas gathering pipeline. According to the CEO, “increased capacity has resulted in a record day of approximately 316,500 MMBtu of natural gas”. >>> VIEW PR


Options Trading Idea: PBR Calls 

We’re interested in the PBR October 31st $15.50 Calls  last traded at 1.88. If we can see PBR make its way back to recent $20+ highs within a month, it could put us in position to see returns of up to 150-200% on those contracts.


Extended Watchlist:
 RNN, MNKD, CNET, VHC, MPET

Blue Horseshoe Stocks: CNET Recap & More

ChinaNet Online Holdings, Inc. CNET

CNET made an excellent move following its inclusion in yesterday’s morning report, as the stock would go on to trade in an impressive range from  a low of 2.41 up to a new annual high of 3.98 on nearly 34x its one-month average volume. The strong 65% intraday run came in the first hour of trading, so folks had the chance at some very rapid, very substantial gains. Congrats if you were among them!


Direxion Daily Jr Gld Mnrs Bear 3X ETF (JDST)

We introduced JDST as a way to leverage against the falling prices of gold yesterday, and it’s working out in our favor so far. This ETF didn’t waste any time Monday morning, as it began a morning ascent that would last all day and carry it from a low of 14.65 to 16.88, a modest yet solid gain of 15%

We’ll have our eyes on this one for as long as it appears that the dollar will continue to strengthen.


OTHER ITEMS OF INTEREST

Our scanner yielded three interesting plays with news out of varying subjects.

NXT-ID, Inc. NXTD, has a mobile wallet product that they bill as the truly the first universal secure payment solution, which, as it does not require a smart-phone, provides certain advantages over other eWallet-type products now being pushed by Apple (ApplePay) among others. The stock made a significant move in yesterday’s trading, and will be on our radars today. >>> Shareholder Update PR

China Jo-Jo Drugstores, Inc. CJJDreleased financials yesterday and received a warm reception from traders. Some of the highlights included:

  • Online sales contributed $2.6 million in revenue, an increase of 103.5% from the comparable quarter of prior year
  • Retail sales, which includes online sales, accounted for approximately 80.0% of total revenue, and increased by $2.3 million, or 20.7% year over year to $13.2 million
  • Wholesale, which accounted for approximately 20.0% of total revenue, decreased to $3.3 million from $4.4 million for the same quarter of last year. >>> VIEW FULL PR

Synthetic Biologics, Inc. SYN Earlier last wee the FDA granted orphan drug status to SYN’s monoclonal antibody (mAb) combination, “SYN-005”. After a period of consolidation off of the initial run that produced, the stock is gapping up in the premarket today, so we’ll definitely want to keep an eye peeled.


Extended Watchlist:
OTIV, NETE, NVAX, USAT